Folate-poly-L-lysine- Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery

National Medical Journal of China

Volumn 87, Issue 10, 2007, Pages 673-678

  Yuan, Zheng ^a   Liu, Shi Yuan ^b   Xiao, Xiang Sheng ^b   Zhong, Gao Ren ^b   Jiang, Qing Jun ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Folic; Gadolinium DTPA; Lung neoplasms; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIUM; FOLATE RECEPTOR; FOLIC ACID PLUS GADOLINIUM PENTETATE POLYLYSINE; GADOLINIUM; GADOLINIUM CHLORIDE; PENTETATE CALCIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG TARGETING; FEASIBILITY STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; IMAGE QUALITY; LUNG TUMOR; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; CARRIER PROTEINS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; FOLIC ACID; GADOLINIUM DTPA; HUMANS; LUNG NEOPLASMS; LYSINE; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CELL SURFACE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 34249830168     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Weissleder R, Mahmood U. Molecular imaging. Radiology, 2001, 219:316-333.
2. Earls JP, Bluemke DA. New MR imaging contrast agents. Magn Reson Imaging Clin N Am, 1999,7:255-273.
3. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol, 2006, 60:314-323.
4. Choi H, Choi SR, Zhou R, et al. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol, 2004,11:996-1004.
5. Ke CY, Mathias CJ, Green MA. The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol, 2003,30:811-817.
6. Rollo FD. Molecular imaging: an overview and clinical applications. Radiol Manage,2003,25: 28-32.
7. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev, 2000,41:147-162.
8. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev, 2004,56: 1127-1141.
9. Lu Y, Low PS. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J Control Release,2003,91:17-29.
10. Xu L, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release, 2001,74:115-128.
11. Hattori Y, Maitani Y. Enhanced in vitro DNA transfection efficiency by novel folate-linked nanoparticles in human prostate cancer and oral cancer. J Control Release, 2004, 97:173-183.
12. Unger EC, Totty WG, Neufeld DM, et al. Magnetic resonance imaging using gadolinium labeled monoclonal antibody. Invest Radiol, 1985,20: 693-700.
13. Chinese source.
14. Chinese source.
15. Chinese source.
16. Konda SD, Aref M, Wang S, et al. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA, 2001,12:104-113.
17. Chinese source.
18. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to pratice. Pharmacol Rev, 2001, 53:283-318.